Currently available cytotoxic drugs do not discriminate between cancer and normal cells undergoing rapid division, although some antiestrogen and aromatase inhibitors offer a greater breadth of endocrine therapy and lower toxicity than some other drugs. This evidence concerns the gene CYP19A1 and cancer.